DI-UMONS : Dépôt institutionnel de l’université de Mons

Recherche transversale
(titres de publication, de périodique et noms de colloque inclus)
2017-03-07 - Colloque/Présentation - poster - Anglais - 1 page(s)

Fanfone Deborah , Stanicki Dimitri , Fossepre Mathieu , Surin Mathieu , Rorive Sandrine, Vander Elst Luce , Laurent Sophie , Muller Robert , Saussez Sven , Burtea Carmen , "Development of peptide vectorized contrast agents targeting galectin-1 in the context of imaging diagnosis of papillary thyroid cancer" in Mardi des Chercheurs (MdC2017), Mons, Belgique, 2017

  • Codes CREF : Histologie (DI3212), Sciences biomédicales (DI3200), Endocrinologie (DI3322), Biologie moléculaire (DI3111), Imagerie médicale, radiologie, tomographie (DI3243), Cancérologie (DI3349)
  • Unités de recherche UMONS : Chimie des matériaux nouveaux (S817), Chimie générale, organique et biomédicale (M108), Anatomie et Biologie cellulaire (M112)
  • Instituts UMONS : Institut des Sciences et Technologies de la Santé (Santé), Institut des Biosciences (Biosciences)
  • Centres UMONS : Centre de Recherche en Microscopie et Imagerie Médicale (CMMI)

Abstract(s) :

(Anglais) These last decades, the incidence of thyroid cancers has increased. The diagnostic challenge consists in the distinction of benign and malign nodules. Overexpressed in several human cancers including thyroid, galectin-1 was targeted using peptides that were then conjugated to iron oxide nanoparticles for imaging diagnosis. Immunohistochemistry studies confirmed the specific affinity of peptides 1/7. Immunofluorescence assays proved the colocation of peptides and of vectorized nanoparticles with galectin-1 in TPC-1 cells. No toxicity was observed in hepatocytes. The contrast agents will be soon evaluated in a murine model of papillary thyroid cancer. Concerning the therapeutic approach, peptides (500 nM) induce a decrease in TPC-1 adhesion by interacting with gal-1.